Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins
- PMID: 8165616
Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins
Abstract
The present study was designed to investigate the action of protamine on the release of tissue factor pathway inhibitor (TFPI) activity by unfractionated (UF) and low molecular weight (LMW) heparin in healthy individuals. 5000 IU UF-heparin or 5000 IU LMW-heparin were given intravenously followed by saline, 5000 U protamine chloride or 5000 U protamine sulfate intravenously after the 10 min blood sample. Then serial blood samples for the measurement of TFPI activity and anti-factor Xa-activity were taken, in order to detect a possible relation between the remaining anti-factor Xa activity after neutralization of LMW-heparin with protamine and TFPI activity and to establish whether or not a rebound phenomenon of plasmatic TFPI occurs. There was no difference in the release and in the kinetics of TFPI by UF- and LMW-heparin with subsequent administration of saline. After administration of protamine TFPI activity decreased immediately and irreversibly to pretreatment values. There were no differences between protamine chloride and protamine sulfate on the effect of TFPI induced by UF- or LMW-heparin. No rebound phenomenon of TFPI activity occurred. In contrast anti-factor Xa- activity, as measured by the chromogenic S2222-assay, issued the known differences between UF- and LMW-heparin. The half-life of the aXa-effect of LMW-heparin was twice as long as of UF-heparin. Protamine antagonized UF-heparin completely and about 60% of the anti-factor Xa activity of LMW-heparin, using chromogenic S2222-method. No differences could be detected for protamine chloride and sulfate form of protamine. It is assumed that protamine displaces heparins from the binding sites of TFPI.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Comparative human pharmacology of low molecular weight heparins.Semin Thromb Hemost. 1989 Oct;15(4):414-23. doi: 10.1055/s-2007-1002741. Semin Thromb Hemost. 1989. PMID: 2554502
-
The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(6):967-80. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989. PMID: 2483715
-
Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.Nephrol Dial Transplant. 1995;10(2):217-22. Nephrol Dial Transplant. 1995. PMID: 7753456 Clinical Trial.
-
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.Blood Coagul Fibrinolysis. 1993 Dec;4 Suppl 1:S39-43. Blood Coagul Fibrinolysis. 1993. PMID: 8180328 Review.
-
Tissue factor pathway inhibitor: proposed heparin recognition region.Blood Coagul Fibrinolysis. 1995 Jun;6 Suppl 1:S50-6. Blood Coagul Fibrinolysis. 1995. PMID: 7647222 Review.
Cited by
-
The Heparin Rebound Phenomenon-Does It Offer Insights Toward Understanding the Pathobiology of Coronary Thrombosis and Its Treatment?J Thromb Thrombolysis. 1995;1(2):157-161. doi: 10.1007/BF01062573. J Thromb Thrombolysis. 1995. PMID: 10603525 No abstract available.
-
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.Neurocrit Care. 2016 Feb;24(1):6-46. doi: 10.1007/s12028-015-0222-x. Neurocrit Care. 2016. PMID: 26714677 Review.
-
Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.Curr Treat Options Neurol. 2017 Jan;19(1):1. doi: 10.1007/s11940-017-0438-5. Curr Treat Options Neurol. 2017. PMID: 28130682 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous